NASDAQ-NMS:ACXP

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Retrieved on: 
Thursday, May 2, 2024
Infection, Clostridioides difficile infection, Congress, University, University of Houston, Vancomycin, Professor, Poster, Recurrence, IIIC, Disease, DNA, Patient, Treatment, Microbiology, Doctor of Pharmacy, Diarrhea, CDI, Fidaxomicin, Clostridioides difficile, Houston Community College, Pharmaceutical industry

The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.

Key Points: 
  • The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.
  • Commenting on his presentation, Dr. Garey stated: "This randomized, active-controlled study showed ibezapolstat was comparable to vancomycin in achieving clinical cure in patients with mild-to-moderate CDI.
  • The presentation and poster are available on the Acurx Pharmaceuticals website following their respective presentations at the conference.
  • www.acurxpharma.com
    The complete Phase 2 results are being prepared for submission to a prominent scientific journal.

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Retrieved on: 
Tuesday, April 23, 2024
Infection

STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, at 8:00 am ET before the U.S. financial markets open.

Key Points: 
  • STATEN ISLAND, N.Y., April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, at 8:00 am ET before the U.S. financial markets open.
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

Retrieved on: 
Monday, March 4, 2024
Infection

STATEN ISLAND, N.Y., March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.

Key Points: 
  • STATEN ISLAND, N.Y., March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

Retrieved on: 
Tuesday, January 23, 2024
Infection, Conference

STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.

Key Points: 
  • STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.

Thinking about buying stock in Endeavour Silver, Exxon Mobil, Sealsq Corp, Fusion Pharmaceuticals, or Acurx Pharmaceuticals?

Retrieved on: 
Wednesday, January 17, 2024
Multimedia

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Retrieved on: 
Wednesday, October 25, 2023
Infection, Pharmaceutical industry, Management

STATEN ISLAND, N.Y., Oct. 25, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2023 financial results on Tuesday, November 14, 2023, at 8:00 am ET before the U.S. financial markets open.

Key Points: 
  • STATEN ISLAND, N.Y., Oct. 25, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2023 financial results on Tuesday, November 14, 2023, at 8:00 am ET before the U.S. financial markets open.
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Thinking about buying stock in Profrac Holding, Camber Energy, Acurx Pharmaceuticals, 89bio, or SuperCom Ltd.?

Retrieved on: 
Wednesday, October 11, 2023
Multimedia, Wall Street, Main Street, Security (finance)

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Thinking about buying stock in Kosmos Energy, BioLine RX, BTCS Inc, OSI Systems, or Acurx Pharmaceuticals?

Retrieved on: 
Monday, October 2, 2023
Main Street, Wall Street, Multimedia, Retail

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

Retrieved on: 
Tuesday, August 22, 2023
Infection, Conference, Pharmaceutical industry

STATEN ISLAND, N.Y., Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

Key Points: 
  • STATEN ISLAND, N.Y., Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference.
  • Investors may listen to the presentation online beginning on September 11 at 7:00 A.M. (ET) via the link below.

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

Retrieved on: 
Monday, July 24, 2023
Infection, Pharmaceutical industry, Management

STATEN ISLAND, N.Y., July 24, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2023 financial results on Monday, August 14, 2023, at 8:00 am ET before the U.S. financial markets open.

Key Points: 
  • STATEN ISLAND, N.Y., July 24, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2023 financial results on Monday, August 14, 2023, at 8:00 am ET before the U.S. financial markets open.
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: